Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential
PR Newswire•22/10/2026•16:30 ET
0
Key Highlights
- ➤Labcorp (LH), FDA and Charles River launch abuse-potential research collaboration
- ➤Study will use harmonized behavioral economics methodology to rank abuse potential
- ➤Labcorp contributes regulatory abuse-potential study expertise to collaboration
- ➤FDA scientists will analyze data and provide regulatory science expertise
- ➤Labcorp has supported abuse-potential evaluation studies since 2009
Expert Statements
Brian Caveney, EVP and president, biopharma laboratory services, and chief medical and scientific officer, Labcorp
“This research has the potential to improve how abuse-related risks are evaluated and inform decisions throughout drug development and regulatory review.”
Brian Caveney, EVP and president, biopharma laboratory services, and chief medical and scientific officer, Labcorp
“Ultimately, this work can support safer therapies, stronger regulatory decision-making and improved protections for patients and communities.”
Labcorp, Charles River and FDA Announce Research Collaboration to Advance Preclinical Methods for Evaluating Drug Abuse Potential PR Newswire
Research collaboration aims to strengthen the science used to assess whether new medicines could be abused, supporting safer drug development and more informed regulatory decisions
Get started
Create a free account to read the full story.